GO
Loading...

Enter multiple symbols separated by commas

Roche Holding AG

More

  • NEW YORK, June 30- The United States says Novartis AG should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In papers filed Monday night in Manhattan federal court, the government said it deserves that sum under the federal False Claims Act over...

  • The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid. Sequenom's innovation was in finding a way to use DNA found in maternal blood samples that had previously been discarded as medical waste in order to determine...

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments. Sales of Eylea in the United States leapt 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handsomely beat the average analyst...

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • IBM's Watson to guide cancer therapies at 14 centers Tuesday, 5 May 2015 | 2:00 PM ET

    NEW YORK, May 5- Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp's Watson computer system to choose therapies based on a tumor's genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Faced with such a data deluge, "the solution is going to be...

  • Novartis warns of currency drag on 2015 earnings Thursday, 23 Apr 2015 | 2:07 AM ET

    Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.

  • Europe ends mixed as investors digest earnings Wednesday, 22 Apr 2015 | 12:23 PM ET

    European shares finished mixed on Wednesday, as investors digested a slew of earnings from European companies.

  • Roche CEO downplays hit from Swiss franc on results Wednesday, 22 Apr 2015 | 3:16 AM ET

    Roche, the world's biggest maker of cancer drugs, reported a 3 percent rise in sales in the first quarter on Wednesday.

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • Lightning Round: It's too hot to touch Monday, 6 Apr 2015 | 6:51 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • NEW YORK, March 22- As the dollar surged in the last 12 months, David Marcus, head of the Evermore Global Value fund, steadily increased his stake in Europe. Demand for a way to hedge currency exposure while investing in Europe helped the WisdomTree Europe Hedged Equity Fund bring in $5.3 billion in new assets over the first two months of the year, the most of any equity...